# MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) · Edgar & Edgarette company card

> Matinas Biopharma Holdings (MTNB) saw revenue fall 65.6% in FY2023 to $1 million, operating margin -2168% against a -3.8% median for pharmaceutical preparations, equity 76.7% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1582554 · fiscal year ended 2023-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/MTNB) · [JSON](https://www.pops4.com/boards/company/MTNB.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $1M |
| Revenue growth, 1 year | -65.6% |
| Revenue growth per year | 86.9% |
| Operating margin | -2168.4% (prior year -771.3%) |
| Net margin | -2093.2% |
| Operating cash flow | −$15M |
| Capital spending | $218,000 |
| Free cash flow | −$15M |
| Cash | $5M |
| Long-term debt | — |
| Total assets | $25M |
| Total equity | $19M |
| Equity ÷ assets | 76.7% |
| Return on equity | -119.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -22.34 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative (-$7.0M in FY2025); revenue is hard to predict: its 80% range is ±77%

## Edgarette's reading

Exposure: revenue $1.1M (FY2023). Experience: revenue down 65.6% on the year, up 86.9% a year over 4 years; operating margin -2168.4%, down from -771.3%. Soundness: equity 76.7% of assets, return on equity -119.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $443K and $3.3M next year (method v4.1: its own 4-year record of growth weighed at 50% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $386K to $3.9M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -2168.4% against a -3.8% median; growth -65.6% against 13.7%.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 3, latest 2026-09-04 ([filing](https://www.sec.gov/Archives/edgar/data/1582554/000149315226041577/0001493152-26-041577-index.htm))
- Item 5.02 Director or officer change: 4, latest 2026-07-13 ([filing](https://www.sec.gov/Archives/edgar/data/1582554/000149315226032938/0001493152-26-032938-index.htm))

## Recent filings

- 8-K · filed 2026-11-03 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1582554/000149315226049802/0001493152-26-049802-index.htm)
- 8-K · filed 2026-09-28 · 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1582554/000149315226044451/0001493152-26-044451-index.htm)
- 8-K · filed 2026-09-16 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1582554/000149315226042954/0001493152-26-042954-index.htm)
- 8-K · filed 2026-09-04 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1582554/000149315226041577/0001493152-26-041577-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1582554/000149315226037748/0001493152-26-037748-index.htm)
- 8-K · filed 2026-07-24 · 1.02 Termination of a Material Definitive Agreement · [filing](https://www.sec.gov/Archives/edgar/data/1582554/000149315226034601/0001493152-26-034601-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001582554.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1582554

## Cite

POPS4, Edgar & Edgarette: MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/MTNB. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2023, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.